InsiderSignalSign in

← Insider buys

STOK

Stoke Therapeutics, Inc. · Healthcare

Insiders sold $7.7M of Stoke Therapeutics, Inc. in the last 12 months and bought none

$0Bought, 12 mo

$7.7MSold, 12 mo

$1.6BMarket cap

STOK over the last year

No insider buys filed in this year

STOK after insider buys

3 months after each buy, from the first price a copier could get.

No buys have 3 months of prices yet. A record shows here at 3.

Every filing

101 insider filings since 2019, newest first

Barry Ticho · Chief Medical Officer

$27K−5.2%Oct 2

Barry Ticho · Chief Medical Officer

$170K−21.6%Sep 3

Barry Ticho · Chief Medical Officer

$153K−15.7%Aug 19

Edward M. Md Kaye · Director

$403K−9.2%Aug 19

Jonathan Allan · General Counsel & CORP SEC

$92K−11.9%Aug 19

Barry Ticho · Chief Medical Officer

$208K−26.0%Aug 5

Barry Ticho · Chief Medical Officer

$236K−20.8%Jul 6

Jonathan Allan · General Counsel & CORP SEC

$44K−7.5%Jun 18

Barry Ticho · Chief Medical Officer

$55K−4.9%Jun 3

Barry Ticho · Chief Medical Officer

$74K−6.0%May 5

Barry Ticho · Chief Medical Officer

$60K−5.0%Apr 3

Jonathan Allan · GC, Corp Sec

$313K−32.0%Mar 24

Barry Ticho · Chief Medical Officer

$457K−26.0%Mar 19

Thomas Leggett · CFO

$147K−31.0%Mar 19

Jason Hoitt · Chief Patient Officer

$119K−27.0%Mar 19

Jonathan Allan · GC, Corp Sec

$286K−24.0%Mar 19

Arthur Tzianabos · Interim Exec Chair

$174K−12.0%Mar 12

Adrian R. Krainer · Director

$1.3M−11.0%Mar 12

Adrian R. Krainer · Director

$287K−2.0%Mar 4

Edward M. Md Kaye · Director

$433K−21.0%Dec 10

Jonathan Allan · GC, Corp Sec

$128K−25.0%Dec 10

Barry Ticho · Chief Medical Officer

$167K−21.0%Dec 5

Edward M. Md Kaye · Director

$467K−19.0%Dec 5

Jonathan Allan · GC, Corp Sec

$306K−38.0%Dec 5

Barry Ticho · Chief Medical Officer

$121K−21.0%Dec 3

Edward M. Md Kaye · Director

$65K−4.0%Dec 3

Jonathan Allan · GC, Corp Sec

$138K−19.0%Dec 3

Adrian R. Krainer · Director

$1.2M−11.0%Nov 26

Barry Ticho · Chief Medical Officer

$127K−80.0%Nov 5

Barry Ticho · Chief Medical Officer

$121K−80.0%Oct 2

Skorpios Trust · 10% owner

$27.2M−18.0%Sep 23

Barry Ticho · Chief Medical Officer

$149K−80.0%Sep 5

Barry Ticho · Chief Medical Officer

$146K−80.0%Aug 5

Barry Ticho · Chief Medical Officer

$137K−80.0%Jul 3

Huw M. Nash · Chief Business Officer

$33K−100.0%Jul 3

Barry Ticho · Chief Medical Officer

$152K−80.0%Jun 5

Edward M. Md Kaye · CEO

$654K−61.0%May 22

Huw M. Nash · COO, CBO

$770K−100.0%May 22

Jonathan Allan · GC, Corp Sec

$129K−77.0%May 22

Barry Ticho · Chief Medical Officer

$114K−80.0%May 3

Skorpios Trust · 10% owner

$41.8M−25.0%Apr 18

Barry Ticho · Chief Medical Officer

$125K−79.0%Apr 3

Huw M. Nash · COO, CBO

$811K−100.0%Apr 3

Jonathan Allan · GC, Corp Sec

$68K−66.0%Apr 1

Barry Ticho · Chief Medical Officer

$25K−26.0%Mar 19

Edward M. Md Kaye · CEO

$68K−14.0%Mar 19

Stephen J Tulipano · CFO

$25K−17.0%Mar 19

Huw M. Nash · COO, CBO

$25K−27.0%Mar 19

Barry Ticho · Chief Medical Officer

$77K−80.0%Mar 5

Barry Ticho · Chief Medical Officer

$48K−59.0%Feb 5

About Stoke Therapeutics, Inc.

Stoke Therapeutics, Inc. engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in Phase 1 clinical trials for the treatment of autosomal dominant optic atrophy; and Zorevunersen (STK-001), an investigational new medicine for the treatment of Dravet syndrome is being evaluated in phase 3 clinical trials. The company also develops programs focused on various targets, including haploinsufficiency diseases of the central nervous system and eye. It has a license and collaboration with Biogen Inc. for the development and commercialization of zorevunersen medicine for the treatment of Dravet syndrome; and Acadia Pharmaceuticals Inc. for the discovery, development, and commercialization of novel RNA-based medicines for the treatment of genetic neurodevelopmental diseases. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.